Aggressiveness in clear cell renal cell carcinoma highlighted through CBX4 radiogenomic evidence: a cross-sectional study

Read full text Summarise with VIRAT
Authors: Federico Greco, Andrea Panunzio, Edoardo Montanari, Marco Cataldo, Alessandro Tafuri, Bruno Beomonte Zobel, Carlo Augusto Mallio
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Radiogenomics integrates imaging features with genomic data to improve biological understanding and support personalized risk stratification in oncology. Clear cell renal cell carcinoma (ccRCC) exhibits substantial molecular and radiological heterogeneity. Chromobox 4 (CBX4), a polycomb group protein with known oncogenic activity, has been implicated in promoting tumor proliferation, migration, and adverse outcomes in ccRCC. However, its potential radiogenomic signature has not been previously characterized. The purpose of this article is to evaluate whether CBX4 expression correlates with computed tomography (CT) features associated with aggressive tumor behavior in ccRCC. Methods: CBX4 expression was extracted from The Cancer Genome Atlas (TCGA) RNA-sequencing data. Clinical characteristics and CT features (such as tumor size, margin definition, growth pattern, infiltration, and collateral vascular supply) were collected. Data collection and download were performed on November 1, 2019, and data collection continued for the following five months. Patients were identified from the TCGA-Kidney Renal Clear Cell Carcinoma (KIRC) project according to predefined inclusion and exclusion criteria. Inclusion criteria comprised a histological diagnosis of ccRCC, availability of pre-treatment contrast-enhanced CT scans, and corresponding RNA-sequencing data within the TCGA-KIRC database. Individuals were excluded if imaging data were missing or of inadequate quality, or if matched gene expression data were unavailable. The final study cohort consisted of 206 patients who fulfilled all eligibility requirements. Associations were assessed using Wilcoxon rank-sum, Chi-square, and Fisher’s exact tests. Results: Among 206 ccRCC patients included in this cross-sectional study (42.2% CBX4-positive), CBX4 expression was associated with larger tumors (P=0.002), higher grade (P=0.04), advanced stage (P=0.02), ill-defined margins (P=0.01), ≥50% exophytic growth (P=0.03), collateral vascular supply (P=0.03), and infiltration (P=0.01). Conclusions: CBX4 expression is associated with CT features indicative of more aggressive ccRCC. These results suggest that CBX4 may serve as a radiogenomic marker with potential relevance for non-invasive prognostic stratification. Further prospective studies with standardized imaging protocols and experimental validation are needed to confirm these associations and to clarify the role of CBX4 within precision-oncology pathways.

Fields of Study & Subjects

Radiomics and Machine Learning in Medical Imaging Renal cell carcinoma treatment Medical Imaging Techniques and Applications

Publication details

Journal / source
Therapeutic Radiology and Oncology
Volume
10
Pages
3–3
Publication date
1 March 2026
Language
EN